There is still considerable controversy concerning the role of androgen therapy for hypoactive sexual desire disorder in females. Clinical trials have shown that exogenous testosterone therapy improves arousability, sexual desire and fantasy, frequency of sexual activity and orgasm, and satisfaction and pleasure from the sexual act. We report our experience of 36-year-old fragile X carrier female presented to our department with low sex drive and subjectively poor arousal for the past 1 year. We decided to treat her with local testosterone in a pump form (1% 5 g twice a week). She responded very well to the treatment, and in 3 weeks her libido and sexual functions improved dramatically. We decided to continue the same treatment for almost 1 year following up her free and total testosterone, complete lipid profiles, liver functions and complete blood picture every 3 months. During the whole course of treatment, she had mild facial acne, which was resolved in 2 months after completing treatment with testosterone. This is our first and only case of this syndrome with low sexual desire disorder treated with local testosterone in a pump form. Based upon our 1 year follow-up, low-dose testosterone is a safe and effective approach in treating hypoactive sexual desire disorder in a fragile X carrier female, provided the patient is monitored every 3 months for blood counts, lipid profiles, liver functions and free and total testosterone levels.
Introduction
The role of androgen in females is a controversial issue for decades. However, we report our first experience of treating a 36-year-old Caucasian fragile X carrier female with hypoactive sexual desire disorder treated with local testosterone application (1% 5 g twice a week) for 1 year without any complications.
Case summary
A 36-year-old fragile X carrier female presented with hypoactive sexual desire with low sex drive and subjectively poor arousal for the past 1 year. She described her complaints as gradual in onset, severe in intensity and mild fatigue. She denied any vaginal dryness, menstrual irregularities, weight changes, depression, stress, behavioral or psychiatric disorders. Her family history was significant for known fragile X syndrome in her father and premature ovarian failure in her elder sister at age 35. She was a carrier of premutation allele in the FMR1 gene, which was detected by PCR and Southern blot assays. She was put on combined oral contraceptive pills for the past 3 years as her sister had premature ovarian failure at age 35.
She visited our endocrinology department because of decreased libido and subjectively poor arousal. Her physical examination had characteristic features of macrocephalia with elongated face, thickened nasal bridge extending to the nasal tip, large protruding ears and dental crowding (Figure 1 ). Her routine blood tests, autoimmune profile ovarian imaging, serum testosterone (free and total), thyroid functions, follicular stimulating hormone and luteinizing hormone, C-reactive protein and cortisol levels were within the normal range except free testosterone, which was minimally subnormal (Table 1) .
On the basis of her complaints, we decided to treat her with local testosterone in a pump form (1% 5 g twice a week). She responded very well to the treatment, and in 3 weeks her libido and sexual functions improved dramatically. She was greatly satisfied with the treatment, which is attested by her husband. We decided to continue the same treatment for almost 1 year following up her testosterone levels, both total and free, lipid profiles, liver function tests and complete blood picture every 3 months. During the whole course of treatment for 1 year, our patient had mild facial acne, which was resolved within 2 months after completing treatment with testosterone.
Discussion
Female sexual dysfunction is a complex problem with multiple overlapping etiologies. Androgens play an important role in healthy female sexual function, especially in stimulating sexual interest and maintaining desire. There are a multitude of reasons why women can have low androgen levels, with the most common reasons being age, oophorectomy, hypothalamic-pituitary abnormalities, adrenal insufficiency, glucocorticoid therapy and the use of exogenous estrogens. 1, 2 In a fragile X carrier state, oral contraceptive pills and premature ovarian failures can lead to low androgen levels. Symptoms of androgen insufficiency include absent or greatly diminished sexual motivation and/or desire (or libido), persistent unexplainable fatigue or lack of energy, and a lack of sense of well-being. Although there is no androgen preparation that has been specifically approved by the Food and Drug Administration for the treatment of women's sexual interest/desire disorder or for the treatment of androgen insufficiency in women, androgen therapy has been used off-label to treat low libido and sexual dysfunction in women for over 40 years. Most clinical trials in postmenopausal women with decreased interest in sexual activities have clearly demonstrated that the addition of testosterone to estrogen significantly improved multiple facets of sexual functioning, including libido, arousal, frequency and satisfaction. 2 No case reports have been published yet explaining the effect of testosterone in a fragile X carrier who behaves as a normal XX female, with few exceptions like premature ovarian failure, which is found in 28% of female fragile X premutation carriers. 3 We have tried to explain a one and one-half year followup in treating hypoactive sexual desire disorder with this disease.
As our patient was on combined oral contraceptives (estrogen and progesterone) for the last 3 years, preventing her from having premature ovarian failure, we started to treat her on testosterone in a pump form while continuing her oral contraceptive pills, which are suggestive for low testosterone levels in women. 4 The relation between serum testosterone level and lack of libido has not been proven yet. However, research findings show that testosterone, together with estrogen, is believed to be involved in the sensations perceived by the brain to be sexual. 1 Davis et al., 5 in their research article, have shown no linear association between specific androgen levels and low sexual function, as measured by scores on the Profile of Female Sexual Function, a validated measure of several domains of female sexual function, including desire, arousal, orgasm, pleasure, sexual concerns, responsiveness and self-image.
A recently published phase III randomized, placebo-controlled crossover clinical trial in female cancer survivors failed to prove the efficacy of transdermal testosterone among estrogen-depleted women who presented with low libido compared to those who had estrogen-repleted levels. 6 This finding correlates with our report, which also showed that our patient had normal estrogen levels and became sexually active when put on testosterone.
As all the experiments of hypoactive desire disorders are conducted on normal females, our experience will open the door for further perspective randomized trials for testosterone with and without estrogen in normal as well as fragile X females.
Currently, the Food and Drug Administration recognizes the role of testosterone in female hypoactive Hypoactive sexual desire disorder in fragile X carrier female S Raza et al desire disorder; however, long-term safety data in women seem an appropriate concern specific to testosterone replacement. Toxicity to low feminine doses of testosterone includes deep voice, oily skin, acne and male-pattern hair loss. Virilization is not common, is usually reversible and typically occurs only with supraphysiologic dosages. Reduced total and high-density lipoprotein cholesterol levels have been demonstrated when testosterone was used in women in addition to estrogen, although the long-term effects on heart disease are not known. Testosterone use in the short term has not been associated with an increase in cardiovascular disease or symptoms. [7] [8] [9] Our patient experienced only a mild form of acne, which was a treatment-related expected effect and was well controlled by monitoring free serum testosterone levels, complete blood picture and lipid profile.
Conclusion
Recent studies have clearly documented the role of topical testosterone in females with hypoactive sexual desire disorder, and current trials do validate the effectiveness of combined testosterone and estrogen. However, the Food and Drug Administration is more concerned about the possible effects of long-term application of its use. Our one and onehalf year follow-up and strategy to control the side effects would guide other endocrinologists to use this method of treatment in fragile X carrier syndrome patients. This is our first and only case of this syndrome with low sexual desire disorder treated successfully with local testosterone application in a pump form, and our approach and method to treat her was the same as for a normal XX female with no known genetic instability. In this case report, we conclude that a low dose of testosterone is a safe and effective approach in treating hypoactive sexual desire disorder in fragile X carrier females, provided the patient is monitored every 3 months for complete blood counts, liver functions, complete lipid profiles, and free and total testosterone levels.
